Loading stock data…
ARQT
$21.24+0.07 (+0.33%)
After Hours$20.95-0.29 (-1.37%)· Last close May 11
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arcutis Biotherapeutics, Inc. in the Healthcare sector is trading at $21.24. The stock is currently 33% below its 52-week high of $31.77, remaining 7.9% below its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why ARQT maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$21.24
Potential Upside
5%
Whystock Fair Value$22.30
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.97B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.77
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.22%
Volume
Today's trading volume
3.19M
Recent News
Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE Expansion
In early May 2026, Arcutis Biotherapeutics reported first-quarter revenue of US$105.4 million, reduced its net loss to US$11.3 million, and reaffirmed full-year 2026 net product revenue guidance of US$480 million to US$495 million. The company also filed an sNDA to extend ZORYVE cream 0.05% to infants as young as 3 months with mild to moderate atopic dermatitis, potentially widening its addressable pediatric market with a steroid-free option in a segment that currently has only one other...
Arcutis Biotherapeutics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Arcutis Biotherapeutics, Inc.'s Q1 2026 earnings call
Arcutis Biotherapeutics Q1 Earnings Call Highlights
Arcutis Biotherapeutics (NASDAQ:ARQT) reported first-quarter 2026 net product revenues of $105.4 million, a 65% increase versus the same period last year, as the company pointed to continued demand growth for its topical therapy ZORYVE and progress across a “grow, expand, build” strategy that includ
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of -438.92% and +6.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.